drugset / Trial / NCT07378579
An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001
RandomizedCrossoverTriple-blindTreatment
Summary
This a phase 1, partially blinded, randomized, crossover study to determine the pharmacokinetics (PK) and QT/QTc interval of study drug (ESK-001) in healthy volunteer participants,
Timeline
- Start
- 2024-06-21
- Primary completion
- 2024-08-31
- Completion
- 2024-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ENVUCITINIB | Small molecule | — | Oral |
| Comparator | Moxifloxacin | Small molecule | 400 mg | — |
Indications
No indication recorded.